Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation

• Published in: Transfusion (Philadelphia, Pa.) Vol. 55; no. 2; pp. 253 - 258
• Main Authors: Christou, Grace, Kekre, Natasha, Petrcich, William, Tokessy, Melanie, Neurath, Doris, Giulivi, Antonio, Saidenberg, Elianna, McDiarmid, Sheryl, Atkins, Harold, Bence-Bruckler, Isabelle, Bredeson, Christopher, Huebsch, Lothar, Sabloff, Mitchell, Sheppard, Dawn, Tay, Jason, Tinmouth, Alan, Allan, David S.
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.02.2015; Wiley Subscription Services, Inc
• Subjects: Adult; Allografts; Confidence intervals; Disease-Free Survival; Female; Follow-Up Studies; Health risk assessment; Hematologic Neoplasms - mortality; Hematologic Neoplasms - therapy; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mortality; Platelet Transfusion - mortality; Survival Rate; Thrombocytopenia - etiology; Thrombocytopenia - mortality; Time Factors; Toxicity; Transplants & implants
• ISSN: 0041-1132; 1537-2995
• DOI: 10.1111/trf.12817

Background Thrombocytopenia occurs commonly after hematopoietic progenitor cell transplantation (HPCT) and is associated with potential morbidity and mortality. Few studies have examined the impact of platelet (PLT) transfusion on clinical outcomes in HPCT while optimal PLT transfusion strategies after HSCT remain uncertain. Study Design and Methods A retrospective single‐center cohort study was conducted on 522 patients undergoing HPCT between January 2002 and December 2007. Associations between PLT transfusion events and clinical characteristics with transplant‐related outcomes were assessed using univariate and multivariate analysis. Results Mean number of PLT transfusion events before Day +60 posttransplant was 7.5 (95% confidence interval, 6.7‐8.4) with greater number of events after allogeneic compared with autologous HPCT (p < 0.01). Univariate and multivariate analysis confirmed that the number of PLT transfusion events was associated with increased 100‐day nonrelapse mortality (p < 0.01), posttransplant length of hospital stay (p < 0.01), need for intensive care unit admission (p < 0.01), and number of organs affected by severe toxicity (p < 0.01). Conclusion HPCT‐related toxicity and mortality are associated with increased PLT transfusion events. Alternative strategies to reduce PLT transfusions after HPCT may warrant future study.